351 reports of this reaction
1.9% of all AMLODIPINE BESYLATE AND VALSARTAN reports
#12 most reported adverse reaction
DIABETES MELLITUS is the #12 most commonly reported adverse reaction for AMLODIPINE BESYLATE AND VALSARTAN, manufactured by Novartis Pharmaceuticals Corporation. There are 351 FDA adverse event reports linking AMLODIPINE BESYLATE AND VALSARTAN to DIABETES MELLITUS. This represents approximately 1.9% of all 18,550 adverse event reports for this drug.
Patients taking AMLODIPINE BESYLATE AND VALSARTAN who experience diabetes mellitus should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIABETES MELLITUS is a less commonly reported adverse event for AMLODIPINE BESYLATE AND VALSARTAN, but still significant enough to appear in the safety profile.
In addition to diabetes mellitus, the following adverse reactions have been reported for AMLODIPINE BESYLATE AND VALSARTAN:
The following drugs have also been linked to diabetes mellitus in FDA adverse event reports:
DIABETES MELLITUS has been reported as an adverse event in 351 FDA reports for AMLODIPINE BESYLATE AND VALSARTAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIABETES MELLITUS accounts for approximately 1.9% of all adverse event reports for AMLODIPINE BESYLATE AND VALSARTAN, making it a notable side effect.
If you experience diabetes mellitus while taking AMLODIPINE BESYLATE AND VALSARTAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.